Research programme: oligonucleotide-based therapeutics - Synthena

Drug Profile

Research programme: oligonucleotide-based therapeutics - Synthena

Alternative Names: SYN 416; SYN 510

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synthena
  • Class Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Antisense RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 28 Feb 2017 Preclinical trials in Duchenne muscular dystrophy in Switzerland (Synthena pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top